FindMyKOL

April Armstrong, MD

Enriched profile

Professor and Chief of Dermatology · University of California, Los Angeles (UCLA)

ORCIDNone on fileNPI↗
✓ Itemized profile
Region🇺🇸 Los Angeles, CA · West · United StatesSpecialtyDermatologyFocusAtopic Dermatitis / Eczema+3
Active KOLFindMyKOL type: EliteLatest publicationNone indexedOnline presenceNone verifiedPayments2021–2025NIH funding2009–2026Why? →

April Armstrong is Professor and Chief of Dermatology at University of California, Los Angeles (UCLA). ClinicalTrials.gov lists 15 registered studies with this person as an investigator.

Data verified 27 Oct 2026

Overview

Updated 3 Nov 2026

April W. Armstrong, MD, is Professor and Chief of Dermatology at University of California, Los Angeles (UCLA). It also documents an investigator role on 15 registered clinical trials, industry payments reported by 41 companies, 3 NIH-funded awards (2009–2026).

  • Top research focus: Atopic Dermatitis / Eczema
  • 15 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 41 companies

Generated from the cited public record · current as of 3 Nov 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Atopic Dermatitis / Eczema4 trialsPsoriasis / Psoriatic Arthritis4 trialsSkin Neoplasms3 trialsEczema2 trialsAcne / Hidradenitis2 trialsAcne Vulgaris2 trialsOsteoarthritis1 trialMelanoma1 trialBursitis1 trial

Research focus

OpenAlex concept fingerprint
Atopic Dermatitis / EczemaAcne / HidradenitisAcne VulgarisEczema

Drugs & molecules

across trials, industry payments and publications
Tremfyageneric · GuselkumabClinical trials—Industry payments178Publications—Bimzelxgeneric · BimekizumabClinical trials—Industry payments77Publications—Skyrizigeneric · RisankizumabClinical trials—Industry payments67Publications—Sotyktugeneric · DeucravacitinibClinical trials—Industry payments64Publications—Dupixentgeneric · DupilumabClinical trials—Industry payments47Publications—Ebglyssgeneric · LebrikizumabClinical trials—Industry payments47Publications—Rinvoqgeneric · UpadacitinibClinical trials—Industry payments45Publications—Cosentyxgeneric · SecukinumabClinical trials—Industry payments32Publications—Taltzgeneric · IxekizumabClinical trials—Industry payments22Publications—Vtamageneric · TapinarofClinical trials—Industry payments22Publications—Enbrelgeneric · EtanerceptClinical trials—Industry payments20Publications—Ilumyageneric · TildrakizumabClinical trials—Industry payments20Publications—

Works with

trial sponsors and companies reporting payments
Abbvie Inc.Clinical trials—Industry payments175E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments138Janssen Biotech, Inc.Clinical trials—Industry payments136UCB, Inc.Clinical trials—Industry payments95Lilly USA, LLCClinical trials—Industry payments86Novartis Pharmaceuticals CorporationClinical trials—Industry payments62Eli Lilly and CompanyClinical trials—Industry payments61Genzyme CorporationClinical trials—Industry payments47LEO Pharma Inc.Clinical trials—Industry payments46Amgen Inc.Clinical trials—Industry payments42Boehringer Ingelheim International GmbHClinical trials—Industry payments38Janssen Global Services, LLCClinical trials—Industry payments32Galderma Laboratories, L.P.Clinical trials—Industry payments25Janssen Scientific Affairs, LLCClinical trials—Industry payments24Ucb SaClinical trials—Industry payments22Dermavant Sciences, Inc.Clinical trials—Industry payments21Sun Pharmaceutical Industries Inc.Clinical trials—Industry payments21Regeneron Healthcare Solutions, Inc.Clinical trials—Industry payments17Incyte CorporationClinical trials—Industry payments16Pfizer Inc.Clinical trials—Industry payments13Ortho Dermatologics, a division of Bausch Health US, LLCClinical trials—Industry payments12Takeda Pharmaceuticals U.S.A., Inc.Clinical trials—Industry payments12Novartis Pharma AGClinical trials—Industry payments10Arcutis Biotherapeutics, Inc.Clinical trials—Industry payments8LEO Pharma ASClinical trials—Industry payments8University of California, DavisClinical trials8Industry payments—Janssen Research & Development, LLCClinical trials—Industry payments6Regeneron Pharmaceuticals, Inc.Clinical trials—Industry payments4University of Southern CaliforniaClinical trials4Industry payments—Mindera CorpClinical trials—Industry payments3

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
0citations

Total citations across indexed works.

0h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
15clinical trials

Investigator role on registered studies.

View trials ↓
41companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
3NIH grants · 2009–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 3 Nov 2026

Listed as an investigator on 15 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 3 Nov 2026

41 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Sensory organs

    29.4%
    Corticosteroid29.4%
    Clobetasol Propionate80%Hydrocortisone20%
    Part D≥49 patients
  • Dermatology

    24.2%
    Interleukin-4 Receptor alpha Antagonist13.5%
    Dupixent Pen100%
    Part D<11 patients
    Corticosteroid7.3%
    Triamcinolone Acetonide100%
    Part D≥15 patients

    + 1 more class in this area

  • Anti-infectives

    19.3%
    Azole Antifungal12.8%
    Ketoconazole100%
    Part D≥21 patients
    Lincosamide Antibacterial3.6%
    Clindamycin Phosphate100%
    Part D<11 patients

    + 1 more class in this area

All 5 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)40.7% facility · 59.3% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 3 Nov 2026

3 NIH research awards on record, funded 2009–2026 per NIH RePORTER. The latest:

All 16 award records: search, sort and filter.Explore →

Publications

None on file yet. We only list publications we can confidently match to this person. Why? →

Background & recognition

Updated 3 Nov 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MPH

    Harvard T.H. Chan School of Public Health

    2010
    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
  • Board certified in Dermatology

    American Board of Dermatology

    2008
    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
  • MD

    Harvard Medical School

    2004
    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗

Editorial & leadership roles

journal and society appointments
  • Past Co-President

    Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →grappanetwork.org ↗
  • Board member

    American Academy of Dermatology

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →profiles.ucla.edu ↗
  • Immediate Past Chair

    Medical Board, National Psoriasis Foundation

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucla.edu ↗
  • Editorial board member

    JAMA Dermatology

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
  • Councilor

    International Eczema Council

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →profiles.ucla.edu ↗
  • Councilor

    International Psoriasis Council

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →profiles.ucla.edu ↗
  • Board member

    International Dermatology Outcome Measures

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →profiles.ucla.edu ↗
  • Board member

    California Society of Dermatology and Dermatological Surgery (CalDerm)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →profiles.ucla.edu ↗
  • Past President

    American DermatoEpidemiology Network

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →profiles.ucla.edu ↗
  • Past President

    Sacramento Valley Dermatology Society

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →profiles.ucla.edu ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • Co-Director for Network Resources

    UCLA Clinical and Translational Research Institute

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.